文献速递甲状腺疾病

甲状腺髓样癌中SPECC1L::ALK融合首例报告及阿来替尼显著疗效

First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib.
PubMed 文献 · Thyroid · 2025-05-16

本文报告一例33岁女性转移性甲状腺髓样癌患者,经二代测序(Archer FusionPlex®)检出SPECC1L::ALK基因融合,接受阿来替尼600 mg每日两次治疗。治疗6天后PET-CT显示部分至接近完全缓解,6周确认完全缓解;截至8个月随访仍维持完全缓解,除3级肌痛伴肌酸磷酸激酶升高(经暂停用药和剂量调整处理)外耐受良好。这是甲状腺髓样癌中SPECC1L::ALK融合的首例报告。

要点

  • 甲状腺髓样癌中ALK基因重排罕见,SPECC1L::ALK融合此前未充分研究。
  • 本例转移性甲状腺髓样癌经二代测序检出SPECC1L::ALK融合,阿来替尼600 mg每日两次治疗6天即达部分至接近完全缓解。
  • 治疗6周确认完全缓解,截至8个月随访仍维持完全缓解。

核心结论

  • 这是甲状腺髓样癌中SPECC1L::ALK融合的首例报告。
  • 对阿来替尼的显著反应凸显了分子分型的重要性,并提示ALK抑制剂可能使携带罕见ALK融合的甲状腺癌患者获益。

研究设计与样本

  • 病例报告:一例33岁女性转移性甲状腺髓样癌患者,采用二代测序(Archer FusionPlex®)进行分子分型。

主要发现

  • 分子分型检出SPECC1L::ALK基因融合,随后启动阿来替尼600 mg每日两次治疗。
  • 治疗6天后PET-CT显示部分至接近完全缓解,治疗6周确认完全缓解。
  • 治疗总体耐受良好,出现3级肌痛伴肌酸磷酸激酶升高,经暂时停药和剂量调整处理。
  • 截至最新随访(8个月),患者仍继续阿来替尼治疗并维持完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Rearrangements of the ALK gene are rare in medullary thyroid carcinoma (MTC), with limited data on the efficacy of ALK inhibitors in this context. Novel fusions, such as SPECC1L::ALK, have not been extensively studied. Methods: We present a case of a 33-year-old woman with metastatic MTC, in whom molecular profiling using next-generation sequencing (Archer FusionPlex®) identified a SPECC1L::ALK gene fusion. Treatment with the ALK inhibitor alectinib was initiated at 600 mg twice daily. Results: The patient demonstrated a dramatic partial to near-complete response after 6 days of treatment, as shown by positron emission tomography-computed tomography. At 6 weeks, a complete response was confirmed. Treatment was generally well tolerated, aside from grade 3 myalgia with elevated creatine phosphokinase, managed with temporary cessation and dose adjustment. As of the latest follow-up (8 months), the patient remains on alectinib with sustained complete response. Conclusions: This is the first report of a SPECC1L::ALK fusion in MTC. The dramatic response to alectinib highlights the importance of molecular profiling and suggests that ALK inhibitors may benefit patients with rare ALK fusions in thyroid cancers.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bischoff H, Fattori A, Moinard-Butot F, et al. First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib. Thyroid. 2025. PMID: 40376737. doi:10.1089/thy.2025.0017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。